Abi Siva, Associate Professor and Director of Medical Oncology at MUSC Health Hematology Oncology at Hollings Cancer Center, shared a post by Yakup Ergün, Medical Oncologist at Antalya City Hospital, on X, adding:
“To me, what’s most impressive about the VICTORIA-1 study is the significant improvement seen in a PIK3CA WT population, something we really haven’t seen before.
Makes you wonder what the magnitude of benefit might look like in the mutation cohort when Arm 2 reads out.”
Quoting Yakup Ergün’s post:
“Toxicity and cost are certainly important; however, it is encouraging to see that survival durations are prolonged following CDK4/6 inhibitor therapy.”
Title: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
Authors: Sara Hurvitz, Rachel Layman, Giuseppe Curigliano, Fabrice André, Massimo Cristofanilli, Sung-Bae Kim, Jorge Martínez Rodríguez, Jorge Nadal, Gun Min Kim, Louisa Lo, Yuly Remolina-Bonilla, Geronimo Rosselli, George Emile, Ernesto Korbenfeld, Juan Manuel Puig, Robert Wesolowski, Miguel Martin, Alistair Ring, Hyo Han, Antonio Giordano, Sarah Mutka, Keren Moss, Sam Suzuki, Brian Sullivan, Igor Gorbatchevsky, Barbara Pistilli
Read the Full Article.
Other articles featuring Abi Siva on OncoDaily.
